WHO ARE WE Established  in  1994  as  a  Medical  Technology  Developer  and  Patent  Holding  Company  (Formerly  Known  as  LaMina  Inc.)    

Inventor  of  the  First  Test  in  the  Cup  (Genie  Cup)  for  Drugs  of  Abuse  tesJng,  First  Monolayer  Liquid  PreparaJon  (MonoPrep)  Cytology  to  replace  PAP-­‐Smear  for  Cervical  Cancer  Screening  And  First  Saliva  Based  Colloidal  Gold  (Nanotechnology)  Point  of  Care  and  PaJent  ID  Test.    

BTP(Background)

BTP’s Technology Platform •  BioTechPharma, LLC ("BTP") has developed and patented a

front-end collection and testing platform. e product platform is a ‘One-Step” collection and rapid On-Site testing nanotechnology-based micro#uidic device. e device has a built-in feature to capture test subject's $ngerprints while collecting his/her DNA for sample identi$cation.

•  Essentially, BioTechPharma's platform can be used to test virtually any metabolite, protein, or biomarker found in a human as well as most other environmental or biological samples.

•  BTP's business model is to manufacture, sell, and license its products to the "Point of Care", test screening, environmental and biometric markets. BTP's platform has many applications including but not limited to drug of abuse, infectious diseases, cancer detection, environmental, and bio-defense.

•  e business strategy of the company is to establish strategic partnerships with companies and organizations to exploit the platform for pro$table applications.

http://www.youtube.com/watch?v=giyf0cslVow

Our Vision To  Make  Healthcare  Affordable  To  All  NaJons  Around  the  Globe  And  To  Enable  People  To  be  more  proacJve  about  their  health  to  Do  More  for  Less.  

This  Can  Be  Achieved  Through  InnovaJve  Offerings  And  Unique  Value  ProposiJons  Across  the  Full  Spectrum  of  Healthcare  including  Manufacturing  of  Consumer  Health  Products  and  PaJent  Monitoring  Devices.  

Our Mission To  Provide  an  Affordable  InnovaJve  SoluJons  via  AlternaJve  Offerings  to  the  Healthcare  Community  to  enhance  the  Quality  of  Services  For  Caregivers  while  enhancing  Consumer  Values.  

To  Introduce  New  Trends  in  Healthcare  Consumer  Privacy  &  InformaJon  Security  while  CreaJng  New  OpportuniJes  for  Employments  in  the  rapidly  growing  Healthcare  Economy    

Core Values Commitment  To  Excellence  via  InnovaJon,  Integrity,  and  Social  Responsibility.  

Job  creaJon  to  Enable  Each  In-­‐Country  Partnership  to  parJcipate  in  the  New  Global  Healthcare  economy  

KSA (Introduction) In-Country HealthCare Partnership  

Healthcare Spending as a (%) of GDP for

• Healthcare  environment •  12B+ healthcare spending in capital equipment and related supplies and services, Average annual growth between 5% - 10% • Major Cause of Death: Cardiovascular, Cancer, and Diabetes

•  MOH Total Budget of SR 22B in 2007

•  SR 2000M FMS addressable Market

•  383 hospitals / > 55K beds   324 MOH hosp. / 35,000 beds

  27 military / 4,755 beds

  5 National Guard / 1,530 beds

  5 Teaching Hospitals / 1,770 beds

  ARAMCO / 560 beds

  2 Royal Commission / 949 beds

  15 > 200 beds ( Private) / 9,735 beds

  3 Security Forces Hosp. / 570 beds

  1 KFSH / 500 beds

15

10.9

9.7

8.5

4.3 3.8

4.1

2.7

4.1

USA Ger Fra Italy KSA Kuwait UAE Qatar Bahrain

Estimated KSA Market Size Capital Equipment & Related Consumables and

Services

MOH          MODA        NGHA          KFSH        Teach      Private            Others                                                                            HIT                      Services          Non-­‐Medical        Consumables

 Total  Market  Size          SR  39,860,200  

 Capital  Equipment  

+

Future Market Drivers •  Worldwide: •  Most hospitals, clinics, trauma centers, physicians, and patients

will be connected to one large network enabling access to critical medical information.

•  The medical industry will face an ethical and social issues over the disclosure of patient information that causes patient Information privacy and security to become an integral part of the healthcare systems.

•  Advanced nanotechnology and genetic will eliminate many diseases, accelerate healing, and increase longevity.

•  Personalized Medicine will lead to new generation of smart phone applications, drugs, implants, and medical devices that will enhance our health and performance.

•  Virtual-reality medical simulations will become the dominant mode of medical training.

•  Cyber-health care that is customized for us—designed to monitor, diagnose, educate, and intervene regardless of location or time—will be common.

KSA:

•  Demand for Integrations of clinical IT solutions and wireless healthcare communication devices will drive the need for information security and patient privacy.

•  Growing pressures for direct presence of suppliers and made-in the KSA will continue to increase to create new jobs in the Kingdom.

•  Move to innovation to design and build outreach satellite healthcare centers to provide quality healthcare to remote site populations in the KSA.

•  Increased acceptance for Over The Counter (OTC) and “yellow” products in Saudi Public and Private Hospitals and out-patient clinics

•  Quality level of post-sales-support is increasingly more important to customers than brand names will drive the need for Healthcare Call-Centers and Web-Based Information Sites.

•  Saudi Food & Drugs Agency (S-FDA) – newly established regulatory body Change of competitive landscape..

•  Insurance coverage for early detection and pro-health screening.

BTP Target Users and Market Segments

•  BTP Integrated Sample Collection and Testing Devices are significantly different from other Over–The-Counter (OTC) products. They have a built in tamper proof lock plus a split sample vial for additional laboratory testing.

Integrated Sample Collection & Testing Devices

BTP Current Product Offerings

Saliva

•  Saliva Based Kits for Drugs of Abuse Testing for use at VISA & Immigration offices (Point-of-Entry/OTC) and Roadside Testing of 12 Drugs including Alcohol (available Oct. 2013)

•  Saliva Based Kits for Hormonal & Endocrine Measurements of Diabetes and Nutritional Diseases (Available June 2014)

•  Saliva Based Kits for DNA Analysis for use with Personalized Medicine and Chromosomal Analysis of Genetic Diseases.

•  Cervical & Endometrial Swabs for Detection of Cervical Cancer using HPV Chromosomal Markers and Cervical Cytology. (available Oct. 2014)

•  Saliva Based erapeutic Drug Monitoring Kits

Urine & Other Body Fluids

•  Urine Based (OTC) Drugs of Abuse Kits for 23 different Drugs and Alcohol (available Oct. 2013)

•  Urinary Cardiac Markers for Early Detection of Coronary Heart Diseases and Angina Pectoris. (available June 2014)

•  Urinary Tumor Markers for Bladder Cancers & Kidney Cancers. (Available June 2014)

•  Hormonal & Endocrine Nutritional Urinary Markers for Diabetes and Nutritional Diseases (Available June 2014)

•  Occult Blood in the Stool Detection Kits for Early Detection of Colon Cancers.

Patient Centric HealthCare Service Platform

OTC  Markets  

AT-­‐Home  Test  Kits  

BTP (Subsidiaries & Partners) Manufacturing Capabilities

Medical Device Contract Manufacturing Pharmaceutical Contract Manufacturing

Process Engineering Our Contract Manufacturing Capabilities

BTP (Subsidiaries) Our Customer Lists (Partial)  

Abbott Laboratories. Cole Parmer. Fisher Scienti$c. Baxter. Hofman LaRoche. Johnson & Johnson. Medtronic. Becton Dickinson. School Health. InterAccoustics Sanibel Supply DentSply WHPM LumiQuick

FDA & Regulatory Certi$cations

BTP US Government Certi$cations

BTP (Subsidiaries & Partners)

Is e Right Partner For Your Hospitals Group

To meet your Supply Chain & HealthCare Needs in the New Era of Internet Economy.